相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Ethical issues in stroke thrombolysis revisited
Peter Appelros et al.
ACTA NEUROLOGICA SCANDINAVICA (2021)
In-hospital systems interventions in acute stroke reperfusion therapy: a meta-analysis
Prithvi Santana Baskar et al.
ACTA NEUROLOGICA SCANDINAVICA (2021)
Help-seeking behaviour and subsequent patient and system delays in stroke
Ane Bull Iversen et al.
ACTA NEUROLOGICA SCANDINAVICA (2021)
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke
Eivind Berge et al.
EUROPEAN STROKE JOURNAL (2021)
Characteristics and management of stroke in Korea: 2014-2018 data from Korean Stroke Registry
Han-Yeong Jeong et al.
INTERNATIONAL JOURNAL OF STROKE (2020)
Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke
Shreyansh Shah et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2020)
Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke
Martha Marko et al.
STROKE (2020)
Effect of COVID-19 pandemic on stroke admission rates in a Norwegian population
Espen Saxhaug Kristoffersen et al.
ACTA NEUROLOGICA SCANDINAVICA (2020)
Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances
Brian Scott Alper et al.
BMJ EVIDENCE-BASED MEDICINE (2020)
Reperfusion therapy for minor stroke: A systematic review and meta-analysis
Lihuan Lan et al.
BRAIN AND BEHAVIOR (2019)
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
William J. Powers et al.
STROKE (2019)
Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits The PRISMS Randomized Clinical Trial
Pooja Khatri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis
Shoujiang You et al.
STROKE AND VASCULAR NEUROLOGY (2018)
Reasons and evolution of non-thrombolysis in acute ischaemic stroke
T. Reiff et al.
EMERGENCY MEDICINE JOURNAL (2017)
The American Heart Association's Get With the Guidelines (GWTG)-Stroke development and impact on stroke care
Cora H. Ormseth et al.
STROKE AND VASCULAR NEUROLOGY (2017)
Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis
William N. Whiteley et al.
LANCET NEUROLOGY (2016)
Restriction of therapy mainly explains lower thrombolysis rates in reduced stroke service levels
Christoph Gumbinger et al.
NEUROLOGY (2016)
Repeated Intravenous Thrombolysis for Early Recurrent Stroke Challenging the Exclusion Criterion
Timo Kahles et al.
STROKE (2016)
Outcomes in Mild Acute Ischemic Stroke Treated With Intravenous Thrombolysis A Retrospective Analysis of the Get With the Guidelines-Stroke Registry
Jose G. Romano et al.
JAMA NEUROLOGY (2015)
Thrombolysis in patients with prior stroke within the last 3 months
M. R. Heldner et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
Jonathan Emberson et al.
LANCET (2014)
Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals
Lee H. Schwamm et al.
(2013)
Predictors of Increased Intravenous Tissue Plasminogen Activator Use Among Hospitals Participating in the Massachusetts Primary Stroke Service Program
Natalia S. Rost et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2012)
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Peter Sandercock et al.
LANCET (2012)
Ninety-Day Outcome Rates of a Prospective Cohort of Consecutive Patients With Mild Ischemic Stroke
Pooja Khatri et al.
STROKE (2012)
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
Kennedy R. Lees et al.
LANCET (2010)
Influence of Age on Outcome From Thrombolysis in Acute Stroke A Controlled Comparison in Patients From the Virtual International Stroke Trials Archive (VISTA)
Nishant Kumar Mishra et al.
STROKE (2010)
Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaernic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial
Erich Bluhmki et al.
LANCET NEUROLOGY (2009)
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
Werner Hacke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Reasons why few patients with acute stroke receive tissue plasminogen activator
Kara Z. Bambauer et al.
ARCHIVES OF NEUROLOGY (2006)
Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke
EE Smith et al.
STROKE (2005)
Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility
PA Barber et al.
NEUROLOGY (2001)
分享论文
